What is the half-life of LL-37?
LL-37 has a reported half life of ~minutes systemically (longer locally), given subcutaneous. That is why it is typically dosed daily. A shorter half life means more frequent dosing to keep blood levels steady, a longer one lets you space doses further apart.
Quick facts
- Half-life: ~minutes systemically (longer locally)
- Route: Subcutaneous
- Typical schedule: Daily
- Cycle length: 4 weeks
References
- LL-37, the truncation product of cathelicidin, antimicrobial review — Wang G, Curr Top Med Chem, 2020
- Human antimicrobial/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update — Svensson D et al., Inflammation Research, 2025
- Significance of the LL-37 Peptide Delivered from Human Cathelicidin in the Pathogenesis, Treatment, and Diagnosis of Sepsis — Mankowska A et al., Archivum Immunologiae et Therapiae Experimentalis, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on LL-37
Last updated 2026-06-06.